Diffuse Intrinsic Pontine Glioma
Conditions
Brief summary
This phase I/II trial studies the side effects of panobinostat nanoparticle formulation MTX110 (MTX110) in treating participants with newly-diagnosed diffuse intrinsic pontine glioma. Panobinostat nanoparticle formulation MTX110 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Detailed description
PRIMARY OBJECTIVES: I. To determine the safety and tolerability of repeated administration of MTX110 co-infused with gadoteridol given by intratumoral convection enhanced delivery in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). SECONDARY OBJECTIVES: I. To determine the clinical efficacy of repeated administration of MTX110 given by intratumoral convection-enhanced delivery (CED) in children with newly diagnosed DIPG in the confines of a phase I and early efficacy study. OUTLINE: This is a phase I, dose-escalation study followed by a phase II study. Participants receive panobinostat nanoparticle formulation MTX110 intratumorally (IT) by CED infusion on day 1 or days 1 and 2 as determined by dose level. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity. After completion of study treatment participants are followed up at 30 days and then every 2 months.
Interventions
DRUGPanobinostat Nanoparticle Formulation MTX110
Given IT
Undergo CED
Sponsors
Midatech Pharma US Inc.
Pacific Pediatric Neuro-Oncology Consortium
Sabine Mueller, MD, PhD
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to 21 Years
Healthy volunteers
No
Inclusion criteria
* Patients with newly diagnosed DIPG by magnetic resonance imaging (MRI); defined as patients with a pontine location and diffuse involvement of at least 2/3 of the pons are eligible without histologic diagnosis. For lesions with typical imaging features, biopsy is neither encouraged nor required for eligibility. Tumors that are biopsied will be eligible if proven to be supportive of the diagnosis of a DIPG. Consensus of diagnosis by the study team must be met. * Patients who have completed focal radiotherapy within 14 weeks from time of enrollment are eligible. * Treatment must begin at a minimum of 4 weeks after, but no later than 14 weeks after, the date of completion of focal radiotherapy. * Prior chemotherapy: Patients should be at least 30 days from last chemotherapy dose prior to start of CED infusion, with exception of antibody half-lives. For antibody therapies, at least 3 half-lives of the antibody after last dose of monoclonal antibody should have passed prior to CED infusion. Patients less than 30 days from last chemotherapy dose should be discussed with the study chair(s). * Prior radiation: Patients must have received prior treatment with focal radiotherapy as part of initial treatment for DIPG and had their last dose at least 4 weeks prior to and no later than 14 weeks from the first CED treatment. Standard focal radiation therapy will include 54 to 60 Gy by external beam radiotherapy to the brainstem. * Age ≥ 2 years of age to 21 years. Patients younger than 3 years of age may be enrolled on study at the discretion of the Study Chair(s) if supporting evidence that brainstem lesion represents a brainstem glioma. * Karnofsky Performance Score ≥ 50 for patients \> 16 years of age and Lansky Performance Score ≥ 50 for patients ≤ 16 years of age. Patients who are unable to walk because of paralysis, but who are able to mobilize using a wheelchair, will be considered ambulatory for the purpose of assessing the performance score. * Life expectancy of greater than 12 weeks measured from the date of completion of radiotherapy. * Corticosteroids: Patients who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to registration. * Peripheral absolute neutrophil count (ANC) ≥ 1000/mm\^3. * Hemoglobin ≥ 8g/dl. * Platelet count ≥ 100,000/mm\^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment). * Normal coagulation defined as normal International Normalized Ratio (INR) or per institutional guidelines. * Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 70 milliliters (mL)/minute (min)/1.73 m\^2. * A serum creatinine (mg/dL) based on age/gender as follows: * Age: 2 to \< 6 years; Male: 0.8; Female: 0.8 * Age: 6 to \< 10 years; Male: 1; Female: 1 * Age: 10 to \< 13 years; Male: 1.2; Female: 1.2 * Age: 13 to \< 16 years; Male:1.5; Female: 1.4 * Age ≥ 16 years; Male: 1.7; Female: 1.4 * Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 x upper limit of normal (ULN) for age. * Serum glutamate pyruvate transaminase (SGPT) \[alanine aminotransferase (ALT)\] ≤ 110 U/L. * Serum albumin ≥ 2 g/dL. * Patients with seizure disorder may be enrolled if on non-enzyme inducing anticonvulsants and well controlled. * The effects of MTX110 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and 4 months after completion of MTX110 injection administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. * Able to understand, and willing to sign, a written informed consent document. * Patients who are unable to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.
Exclusion criteria
* Patients who had clinical and/or radiographic (MRI) progression of tumor following external beam radiation therapy. * Patients with metastatic disease, including leptomeningeal or subarachnoid disseminated disease. * Patients with tumor morphology that predicts poor coverage of the majority of the tumor including bilateral thalamic involvement, or cysts that represent \> 50% of cross-sectional areas of the pons. These subjects should be discussed with the study chairs. * Patients who are receiving any other investigational agents or other tumor-directed therapy. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to MTX110 or gadolinium. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Female patients of childbearing potential must not be pregnant or breast-feeding. Female patients of childbearing potential must have a negative serum or urine pregnancy test within 14 days of registration. * Patients with MRI or clinical evidence of uncontrolled tumor mass effect are excluded; the assessment of mass effect should be made by the study chairs and study neurosurgeons prior to any planned CED treatment. * Untreated symptomatic hydrocephalus determined by treating physician. * Patients with evidence of intra-tumoral hemorrhage \> 5 mm maximal diameter. These subjects should be discussed with the study chair. * Subjects with prolonged corrected QT (QTc) (\> 450 msec) will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Participants With Grade 3 or Higher, Treatment-related, Adverse Events | Up to 12 Months | Adverse events and clinically significant laboratory abnormalities which meet Grade 3, 4, or 5 criteria according to Common Terminology Criteria for Adverse Events (CTCAE) classified by investigators and treating physicians as related to study treatment (probable, possible, and definite) will be summarized by maximum intensity/grade. Adverse events will be graded according to CTCAE version 4.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival Rate (OS) at 12 Months | Up to 12 Months | Overall survival is defined as the percentage of participants alive from time of diagnosis up to 12 months. |
Countries
United States
Participant flow
Recruitment details
All participants were only enrolled into Phase 1 of the clinical trial. The phase 2 expansion cohort was not activated for enrollment at behest of pharmaceutical supplier.
Pre-assignment details
Each participant was permitted to have a dose-escalation assigned to subsequent rounds of CED treatment upon review of safety data at each round. A dose-escalation during treatment in a previous participant, determined the starting dosage assigned to the next participant. The first three participants enrolled received escalated doses in the second or third round of CED treatment.
Participants by arm
| Arm | Count |
|---|---|
| Phase 1: Treatment (MTX110) - All Participants Participants receive panobinostat nanoparticle formulation MTX110 IT by CED infusion on day 1 or days 1 and 2 as determined by dose level. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
Panobinostat Nanoparticle Formulation MTX110: Given IT Convection-Enhanced Delivery (CED): Undergo CED | 7 |
| Total | 7 |
Baseline characteristics
| Characteristic | Phase 1: Treatment (MTX110) - All Participants |
|---|---|
| Age, Customized | 8 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 5 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race (NIH/OMB) White | 4 Participants |
| Region of Enrollment United States | 7 participants |
| Sex: Female, Male Female | 1 Participants |
| Sex: Female, Male Male | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 7 / 7 |
| other Total, other adverse events | 7 / 7 |
| serious Total, serious adverse events | 1 / 7 |
Outcome results
Primary
Proportion of Participants With Grade 3 or Higher, Treatment-related, Adverse Events
Adverse events and clinically significant laboratory abnormalities which meet Grade 3, 4, or 5 criteria according to Common Terminology Criteria for Adverse Events (CTCAE) classified by investigators and treating physicians as related to study treatment (probable, possible, and definite) will be summarized by maximum intensity/grade. Adverse events will be graded according to CTCAE version 4.0.
Time frame: Up to 12 Months
Population: While individual participants were assigned to receive separate doses, participants are presented in one Arm/Group due to confidentiality concerns for this rare disease study
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Phase 1: Treatment (MTX110) | Proportion of Participants With Grade 3 or Higher, Treatment-related, Adverse Events | Muscle weakness right-sided (Grade 3) | 0.142 proportion of participants |
| Phase 1: Treatment (MTX110) | Proportion of Participants With Grade 3 or Higher, Treatment-related, Adverse Events | Stridor (Grade 3) | 0.142 proportion of participants |
| Phase 1: Treatment (MTX110) | Proportion of Participants With Grade 3 or Higher, Treatment-related, Adverse Events | Vagus nerve disorder (Grade 3) | 0.142 proportion of participants |
| Phase 1: Treatment (MTX110) | Proportion of Participants With Grade 3 or Higher, Treatment-related, Adverse Events | Gait disturbance (Grade 3) | 0.142 proportion of participants |
| Phase 1: Treatment (MTX110) | Proportion of Participants With Grade 3 or Higher, Treatment-related, Adverse Events | Neutrophil count decreased (Grade 3) | 0.142 proportion of participants |
Secondary
Overall Survival Rate (OS) at 12 Months
Overall survival is defined as the percentage of participants alive from time of diagnosis up to 12 months.
Time frame: Up to 12 Months
Population: While individual participants were assigned to receive separate doses, participants are presented in one Arm/Group due to confidentiality concerns for this rare disease study
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase 1: Treatment (MTX110) | Overall Survival Rate (OS) at 12 Months | 85.7 percentage of participants |